Benefits
MTHFR variant bypass
MTHFR gene variants (C677T, A1298C) lower the activity of the enzyme that makes active folate, most in people with two copies of C677T or one copy of each variant. Methylfolate supplies the active form directly, skipping this step. The practical gap is modest: CDC notes that people with these variants still process folic acid, and those with the C677T TT genotype average about 16% lower blood folate than those with CC.
Homocysteine reduction
In a 24-week randomized trial in 144 women, 208 or 416 mcg/day of methylfolate lowered homocysteine as much as 400 mcg of folic acid. Homocysteine is a blood marker, though: in a pooled analysis of 15 randomized trials, lowering it with B vitamins did not reduce heart attacks or deaths and only slightly reduced stroke.
Pregnancy and preconception folate
Healthful diets with adequate folate may reduce a woman's risk of having a child with a brain or spinal cord defect (neural tube defect). Methylfolate supplies folate in its active form, but it has not been tested for this outcome: CDC states that folic acid is the only form shown to help prevent these defects and that people with MTHFR variants can process folic acid. The landmark prevention trial used folic acid.
Mood support (physician-supervised, high dose)
High-dose L-methylfolate has been studied as an add-on to SSRIs under medical care. In 75 people with a partial or no response to SSRIs, adding 15 mg/day improved response rates and symptom scores more than placebo; in a 148-person trial, a regimen starting at 7.5 mg/day did not. With one positive and one null trial, results are mixed, and this is not standard supplementation.
B12 and methylation cycle support
Methylfolate passes its methyl group to homocysteine through the B12-dependent enzyme methionine synthase, making methionine, which the body uses to build SAMe, an important methyl donor. This is why folate and B12 work together in methylation. It is biochemistry, not evidence that extra methylfolate helps people who already get enough folate.
Cognitive function in aging
Low folate and raised homocysteine are associated with poorer cognitive performance. In a 3-year trial in adults aged 50 to 70 with raised homocysteine, 800 mcg/day of folic acid improved memory and information processing speed versus placebo. Methylfolate itself has little direct trial evidence here, so this use is less established than the homocysteine-lowering effect.
Methylfolate compared with folic acid
Folic acid works for most people, and CDC notes that people with MTHFR variants can process it. Methylfolate is at least as effective at raising folate status, may be less likely to hide the anemia of B12 deficiency, and suits people who prefer the active form. Folic acid is cheaper and is the only form shown to help prevent neural tube defects.
Mechanism of action
End-Product of Folate Metabolism
Folic acid → DHF → THF → 5,10-methyleneTHF → 5-MTHF (via MTHFR). Methylfolate is 5-MTHF, so it bypasses all upstream conversions including the MTHFR step.
Methionine Cycle / Homocysteine Conversion
5-MTHF plus homocysteine gives methionine plus THF (via methionine synthase, which needs B12). Methionine is then used to make SAMe, an important methyl donor for the body's methylation reactions.
MTHFR Variant Biology
C677T produces a heat-sensitive enzyme with reduced activity; homozygotes (TT, about 10% of North Americans) are prone to mildly raised homocysteine when folate status is low. A1298C is milder: homozygotes keep about 60% of normal activity, and people with one copy of each variant keep about 50-60%. Frequency varies by ancestry; CDC notes C677T is more common in Hispanic people.
Neurotransmitter Synthesis
5-MTHF may help keep tetrahydrobiopterin (BH4) active: in biochemical studies it can regenerate BH4 from its oxidized form through a reaction catalyzed by MTHFR (a redox step, not a methyl transfer). BH4 is the cofactor for tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in dopamine and serotonin synthesis. Evidence that this matters in people is limited.
Clinical trials
Two randomized, double-blind trials of L-methylfolate added to SSRIs using a sequential parallel comparison design: 148 patients starting at 7.5 mg/day and 75 patients on 15 mg/day (Papakostas et al. 2012, Am J Psychiatry)
Outpatients with major depressive disorder who had a partial or no response to SSRIs.
In the first trial (7.5 mg/day start), outcomes did not differ from placebo. In the second, 15 mg/day beat SSRI plus placebo on response rate and symptom scores, with about six people treated for one extra responder. Adverse event rates matched placebo. A later post hoc analysis of the second trial linked greater response to markers such as BMI 30 or above, raised inflammation markers and certain genetic variants.
Double-blind, randomized, controlled 24-week trial of daily 400 mcg folic acid, 416 mcg or 208 mcg [6S]-5-MTHF, or placebo (Lamers et al. 2004, Am J Clin Nutr)
144 healthy women.
Homocysteine fell with all three active supplements, and the decrease did not differ significantly between folic acid and either 5-MTHF dose. Plasma folate rose less with 208 mcg 5-MTHF than with 400 mcg folic acid or 416 mcg 5-MTHF, and 416 mcg was no more effective than 208 mcg for homocysteine.